Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (337)	5/31/2001 10:30:40 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 557

(collaboration w/ Tgen/Genovo) Genzyme Reports Progress in Gene Therapy Program, May 31, 2001 genzyme.com This result was achieved with both adenovirus and adeno-associated virus (AAV) vectors, and the effect persisted for six months. AAV vectors, which Genzyme is exploring in a collaboration with Targeted Genetics, are particularly promising for treatment of lysosomal storage disorders such as Fabry disease, as they yield long term expression and appear safer than current-generation adenovirus vectors for the treatment of chronic diseases. These results are likely to be applicable to other storage disorders and will form the basis for a common approach to treating these diseases.